The treatment proposed includes bimekizumab, an IL-17 inhibitor, which has a proven high efficacy in psoriasis, along with a favorable cardiovascular profile and potentially beneficial effects on the course of diabetes and necrobiosis lipoidica, based on available molecular studies and case reports. The gene discussed is IL17A; the disease is necrobiosis lipoidica.